Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 264 of the 266 references it cites were found in a registry or an index; 149 of the 278 sources its claims cite were checked for support.

From serendipity to strategy: molecular glue degraders in cancer therapeutics

Open access
Darling, Sarah, Bajrami, Ilirjana, West, Stephen C. · 2025 · Critical Reviews in Biochemistry and Molecular Biology

Abstract

Targeted protein degradation is an elegant therapeutic strategy that harnesses the cell's own degradation machinery to selectively eliminate target proteins. This approach marks a paradigm shift in drug discovery, moving beyond traditional occupancy-based inhibition toward target degradation, thereby silencing proteins that have historically resisted pharmacological intervention. Degrader molecules function by inducing proximity between target proteins and effectors, most commonly E3 ubiquitin ligases, triggering their ubiquitylation and proteasomal degradation. Molecular glue degraders - monovalent small molecules that promote these neo-interactions - have emerged as powerful tools in this space. Serendipity was once synonymous with molecular glue discovery, but increasing mechanistic understanding is now guiding their rational design. In this review, we trace their evolution from chance discovery, explore the biological mechanisms that underpin molecular glue activity, examine key examples that have advanced into the clinic, and discuss the challenges that remain in harnessing these compounds for broader therapeutic impact.

Overview

CoChat Summary

TL;DR

Molecular glue degraders are monovalent small molecules that induce or stabilize ternary complexes between target proteins and E3 ubiquitin ligases, driving selective proteasomal degradation of proteins previously considered undruggable. This review traces their evolution from serendipitous natural-product and IMiD discoveries toward rational design, highlighting clinical successes and remaining challenges in cancer therapeutics.

Key findings

  • Molecular glue degraders can target proteins lacking defined pockets; the review states that >85% of proteins from disease-causing genes are considered “undruggable,” and that degraders act sub-stoichiometrically rather than through 1:1 occupancy.
  • IMiDs thalidomide, lenalidomide, and pomalidomide degrade IKZF1/IKZF3 via CRBN; lenalidomide also degrades CK1α in 5q-MDS. For IKZF1 degradation, celMoD potency is listed as CFT7455 > mezigdomide > CC-99282 > iberdomide > avadomide > pomalidomide > lenalidomide > thalidomide.
  • Additional glue mechanisms include SPLAMs such as indisulam/e7820 stabilizing RBM39–DCAF15 (ternary Kd 0.1 µM vs DCAF15–RBM39 ~5 µM and DCAF15–indisulam >20 µM), UM171 with InsP6 increasing HDAC1 affinity for CRL3-KBTBD4 by 25-fold, and BI-3802 inducing BCL6 polymerization and SIAH1-mediated degradation.
  • Clinically, >70% of molecular glue degraders in use or trials target IKZF1/IKZF3; 18 PROTACs are in clinical trials, 13 of which use CRL4-CRBN. Iberdomide and mezigdomide are in Phase III, e7820 in Phase II, NVP-DKY709 in Phase I, MRT-2359 in Phase I/II, and KPG-121 in Phase II/III.

Methods

  • Narrative review of published literature on molecular glue degraders, their mechanisms, discovery strategies, and clinical development in cancer.
  • No primary experimental data, systematic search strategy, inclusion criteria, or meta-analysis are reported; the synthesis draws on cited preclinical studies, structural studies, and clinical trials.
  • The review organizes evidence thematically: historical serendipitous discoveries, CRBN/IMiD biology, alternative E3 ligases and glue mechanisms, rational screening/design platforms, and clinical targets including IKZF1/3, IKZF2, GSPT1, RBM39, CK1α, cyclin K, and NEK7.

Limitations

  • The paper states that clinical efficacy of molecular glues is still at an early stage and requires careful monitoring for glue-induced toxicities, including unintended disruption of an E3 ligase’s native substrates, especially with pan-tissue effectors such as CRBN.
  • The paper notes resistance challenges: CRBN mutations occur in approximately 30% of relapsed/refractory myeloma patients versus <1% in newly diagnosed patients; sulfonamides have shown modest clinical responses, and e7820 showed a discrepancy between 50% RBM39 loss in a Phase II trial and 90% loss in preclinical models.
  • Evident from the text: as a narrative review, it does not systematically appraise study quality or provide quantitative synthesis, and several clinical programs are described as ongoing or promising without mature outcome data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/10409238.2025.2564068

Cites

264 of 266 references verified0 citation errors · 2 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC-BY · From the PDF
Image 2
CC-BY · From the PDF
Image 3
CC-BY · From the PDF
Image 4
CC-BY · From the PDF
Image 5
CC-BY · From the PDF
Figure 2 Targeted protein degradation and the degraders. (A) Schematic comparing the mechanism of monovalent and bivalent degraders. PROTACs (right) consist of two ligands joined by a linker to force proximity between an E3 ligase and a target protein. Molecular glues (left) are monovalent molecules able to induce proximity, and ubiquitylation, without a linker. (B) Top: Schematic representing the different types of monovalent and bivalent degraders. Target binding moieties are highlighted in teal, effector binding moieties are colored: E3 ligases (light blue), hydrophobic tags (green), endo-lysosomal recruiters (orange) and autophagy-recruiting effectors (purple). Bottom: Schematic representing the degradation machinery used for each degrader: molecular glues, direct degraders, PROTACs and HyTs all recruit E3 ligases and rely on proteasomal degradation (blue). LYTACs and AUTACs instead rely on lysosomal degradation pathways (red). Red arrows indicate
Figure 2 Targeted protein degradation and the degraders. (A) Schematic comparing the mechanism of monovalent and bivalent degraders. PROTACs (right) consist of two ligands joined by a linker to force proximity between an E3 ligase and a target protein. Molecular glues (left) are monovalent molecules able to induce proximity, and ubiquitylation, without a linker. (B) Top: Schematic representing the different types of monovalent and bivalent degraders. Target binding moieties are highlighted in teal, effector binding moieties are colored: E3 ligases (light blue), hydrophobic tags (green), endo-lysosomal recruiters (orange) and autophagy-recruiting effectors (purple). Bottom: Schematic representing the degradation machinery used for each degrader: molecular glues, direct degraders, PROTACs and HyTs all recruit E3 ligases and rely on proteasomal degradation (blue). LYTACs and AUTACs instead rely on lysosomal degradation pathways (red). Red arrows indicateCC-BY · From the PDF
Figure 3 IMiD/CELMoD-dependent recruitment of CRBN neo-substrates.
Figure 3 IMiD/CELMoD-dependent recruitment of CRBN neo-substrates.CC-BY · From the PDF
A Classical molecular glue degraders
A Classical molecular glue degradersCC-BY · From the PDF
Image 9
CC-BY · From the PDF
Figure 5 Therapeutic success of IMiDs/CELMoDs in haematological and solid cancers.
Figure 5 Therapeutic success of IMiDs/CELMoDs in haematological and solid cancers.CC-BY · From the PDF
Image 11
CC-BY · From the PDF

Verification

Claims the paper makes

117 Valid · 4 Not valid · 72 Not checked · 60 Own results and interpretations

152 more claims · 75 with their cited sources checked

Create a free account to see all 253 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 80
  • Probably not a substantial claim. 25
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

  • Hallmarks of Cancer: The Next Generation

    Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×

    “…belongs to the ikaros family and plays an important role in immune evasion is a transcription factor that has been successfully targeted using a glue degrader approach. tumors evade immune detection by disrupting adaptive immunity, a key hallmark of tumor progression (Hanahan and weinberg 2011).”
  • Tissue-based map of the human proteome

    Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286 · cited 2×

    “…across the human tissue proteome showed that cRBN exhibits low tissue specificity, with medium or high expression scores across 44 tissue types (uhlén et al. 2015). cRBN’s pan tissue expression highlights its capacity to target a diverse array of aberrant proteins in disease-specific contexts,…”
  • Science

    (2023) · doi:10.1126/science · Cited by 6,063

  • Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

    Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588

  • PD-1 and Its Ligands in Tolerance and Immunity

    Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 1×

    “Many cancers overexpress PD-l1, triggering this checkpoint and evading immune detection (Keir et al. 2008; Francisco et al. 2010).”
  • Genomic classification and prognosis in acute myeloid leukemia

    Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · cited 1×

    “Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014; Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018). in AMl, RBM39…”
  • Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes

    Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116 · cited 2×

    “A race ensued; their combined research revealed that these natural products remodeled their target proteins, a group of proteins named the immunophilins, recruiting novel interacting proteins to form entirely new ternary complexes (liu et al. 1991; Brown et al. 1994; Sabatini et al. 1994).”
  • PROTAC targeted protein degraders: the past is prologue

    Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · cited 1×

    “Monovalent and bivalent degraders have been extensively reviewed elsewhere (Farnaby et al. 2021; Kastl et al. 2021; Békés et al. 2022; Konstantinidou and Arkin 2024; lemaitre et al. 2024; Robinson et al. 2024; tan et al. 2024; Zhong et al. 2024). in this review, we focus on molecular glue…”
  • Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

    Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609 · cited 3×

    “…while auxin was the first molecular glue degrader to be described, it was not the first recorded use of induced proximity as a tool for targeted protein degradation. the concept of targeted protein degradation was first introduced by crews, Deshaies and colleagues in 2001 (Sakamoto et al. 2001).”
  • Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

    Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 1×

    “…that thalidomide could be repurposed as an anti-cancer agent. clinical trials in multiple myeloma showed promising results where it was thought that its anti-inflammatory properties could disrupt the dependence of myeloma on inflammatory signaling (Singhal et al. 1999; Barlogie et al. 2001).”

Show all 258 references

Cited by

See all 10

Metadata

Authors
Darling, S., Bajrami, I., & West, S. C.
Affiliations
The Francis Crick Institute (GB)
Corresponding author
  • Darling, Sarah
  • West, Stephen C.
Venue
Critical Reviews in Biochemistry and Molecular Biology
Published
2025-10
Volume
60
Issue
4-6
Pages
200-230
ISSN
  • 0045-6411 (ISSN-L)
  • 1040-9238
  • 1549-7798
OpenAlex
W4414691781
Cited by
9
References
258
Citations by year
2026: 9
FWCI
0.68
Type
journal article
Language
en
Open access
Locations
  • Critical Reviews in Biochemistry and Molecular Biology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
Francis Crick Institute (cc2098)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Keywords
molecular glues, targeted protein degradation, E3 ubiquitin ligase, ubiquitination, proteasomal degradation, cancer therapeutics, small molecule drug discovery
MeSH terms
Animals, Antineoplastic Agents, Humans, Neoplasms, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Ubiquitination, Drug Discovery, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: From serendipity to strategy: molecular glue degraders in cancer therapeutics. https://app.cochat.ai/papers/10.1080/10409238.2025.2564068
The paper
Darling, S., Bajrami, I., & West, S. C. (2025). From serendipity to strategy: molecular glue degraders in cancer therapeutics. Critical Reviews in Biochemistry and Molecular Biology. https://doi.org/10.1080/10409238.2025.2564068

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.